Allergic rhinitis. Vasomotor and allergic rhinitis
Conditions
Interventions
Intervention 1: Intervention group: Patients receiving two sprays of mometasone and allanthin with doses of 25 micrograms and 665 micrograms twice a day (every 12 hours). Intervention 2: Control group
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: Allergic rhinitis diagnosis by a clinical allergist collaborating in the project (based on the presence of clinical symptoms such as sneezing, nasal congestion, nasal secretions, and nasal itching or based on a positive prick test or a positive IgE specific to allergens) Age 6-12 years old Obtaining written informed consent from parents
Exclusion criteria
Exclusion criteria: Known history of nasal polyps, other clinically significant respiratory system abnormalities Structural abnormalities of the nose Septum deviation Chronic, acute, or significant sinusitis or post-nasal drip (PND) Drug-induced rhinitis; active pulmonary disorder or infection (e.g., bronchitis, pneumonia, or influenza) Upper respiratory tract or sinus infection within the past 14 days Other important clinical abnormalities of the respiratory system
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: Days 7, 1 and 14 after intervention. Method of measurement: Pediatric Rhino Conjunctivitis Quality of Life Questionaire( PRQLQ). | — |
Secondary
| Measure | Time frame |
|---|---|
| TNSS questionnaire. Timepoint: Days 7, 1 and 14 after the intervention. Method of measurement: TNSS questionnaire(Total Nasal Symptom Score: TNSS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamidreza Hoshmand
Oroumia University of Medical Sciences
Outcome results
None listed